BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1GLOBAL Enables N26 to Become Germany’s first Digital Bank to offer eSIM Mobile Plans13.5.2025 14:30:00 CEST | Press release
In a move set to reshape the intersection of fintech and telecom, 1GLOBAL, a technology-driven global mobile communications provider, has teamed up with N26 to enable it to become the first digital bank in Germany to offer local mobile plans. This partnership will grant N26’s German customers seamless access to flexible, affordable, and contract-free mobile connectivity—all activated directly through the N26 app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513954446/en/ 1GLOBAL, a technology-driven global mobile communications provider, has teamed up with N26 to enable it to become the first digital bank in Germany to offer local mobile plans. By integrating 1GLOBAL’s cutting-edge API, N26 has unlocked a frictionless mobile experience that eliminates the need for physical SIM cards, lengthy contracts, or cumbersome paperwork. Customers can activate their mobile plans in a few taps, enjoying instant connectivity that mi
Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics13.5.2025 14:05:00 CEST | Press release
Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics, a pioneering epigenetic editing company. This honor celebrates the teams’ partnership and sets a benchmark for CRO–biotech partnerships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513574699/en/ Novotech is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics. The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals. Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, acce
KnowBe4 Report Reveals Security Training Reduces Global Phishing Click Rates by 86%13.5.2025 14:00:00 CEST | Press release
KnowBe4’s 2025 Phishing by Industry Benchmarking Report shows a drop in the global Phish-prone™ Percentage (PPP) to 4.1% after 12 months of security training KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today launched its “Phishing by Industry Benchmarking Report 2025” which measures an organization’s Phish-prone™ Percentage (PPP) — the percentage of employees likely to fall for social engineering or phishing attacks, indicating the organization’s overall susceptibility to phishing threats. This year’s report found a global average baseline PPP of 33.1%, meaning a third of employees interact with phishing simulations before taking part in best-practice security awareness training (SAT). The data underscores the significant impact of SAT in mitigating risk. The rapid decline in the global PPP following the implementation of training — falling by 40% in just three months and by a total of 86% after 12 months — demonstrates that
Armis Announces New Global Technology Integration Partners to Bolster Organizations’ Cyber Resilience13.5.2025 14:00:00 CEST | Press release
Strategic partnerships enhance and optimize technology stacks for joint customers Armis, the cyber exposure management & security company, today announced that it has added 10 global technology integration partners over the past quarter. These integrations increase the functionality and efficiency of organizations’ existing technology stacks with added benefits from Armis’ platform and solutions. “Relying on siloed security solutions is no longer enough to gain a comprehensive, real-time understanding of an organization’s attack surface,” said Nadir Izrael, CTO and Co-Founder at Armis. “Integrating Armis’ best-in-class platform with other leading vendors’ offerings empowers businesses to consolidate their technology stacks. By driving greater value in their security investments, organizations can ensure their entire attack surface is continuously defended and managed.” New Armis global technology integration partners include AnzenOT, Brinqa, ColorTokens, EasyVista, SaltyCloud, Salvador
Kyriba Unveils Agentic AI TAI to Transform Finance with Security, Compliance & Trust13.5.2025 13:35:00 CEST | Press release
Liquidity Performance Leader to Fill ‘Trust Gap’, Empower CFOs to Outperform Volatility Kyriba, a global leader in liquidity performance, today introduced its agentic AI solution, TAI – a significant advancement in the safe, compliant use of generative AI in finance operations to improve productivity and efficiency amid continued economic uncertainty. Powered by Kyriba's embedded Large Language Model (LLM) and over 20 years of unmatched global liquidity data, TAI simplifies complex workflows, identifies risks with predictive analytics, and enhances data-driven decision-making across treasury, payments, risk management and working capital. Poised to transform finance and treasury operations without relying on third-party LLM integrations, TAI is a key component of Kyriba’s Trusted AI portfolio. This platform-wide approach prioritizes industry-leading data privacy while empowering enterprise leaders to make faster, smarter decisions with human judgement and responsibility at the center.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom